BEIJING (Reuters) – Supplies of Pfizer’s Paxlovid in China are still unable to meet demand but local production of the anti-viral COVID drug should be able to start soon, a Chinese health expert said on Wednesday.
Wang Qingquan, head of the infectious diseases department at Peking University First Hospital, made the comment at a press conference.
(Reporting by Yew Lun Tian; Writing by Brenda Goh; Editing by Jacqueline Wong)
